Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

Inclusion Criteria: All cohorts: * Female subjects more than 18 years of age * Performance status must be ECOG 0-2. * Adequate organ function * Measurable disease by RECIST version 1.1 or CA125 progression according to the GCIG definition (Vergote et al). * Written informed consent Ovarian, fallopian tube or peritoneal carcinoma cohort: * Histologically confirmed diagnosis of invasive epithelial ovarian,fallopian tube, or peritoneal carcinoma (serous, mucinous, endometrioid,clear cell, or carcinosarcomas are eligible). * Patients should have received at least 1 earlier platin treatment but should be platin refractory (progression within 28 days after the last dose of platin) or platin resistant (progression within 6 months after last dose of platin therapy). * Earlier weekly or dose-dense regimens with paclitaxel and carboplatin are not allowed. Consolidation after the last platin dose with non-platinum containing chemotherapy or molecular targeted drugs is allowed Endometrial carcinoma cohort * Histologically confirmed diagnosis of endometrial carcinoma (endometrioid,adenoacanthoma, adenosquamous, serous, clear cell carcinoma or carcinosarcomas are eligible). * Recurrent or advanced endometrial carcinoma can be included. * Earlier platin therapy is allowed. But earlier weekly or dose-dense regimens with paclitaxel and carboplatin are not allowed. Cervical carcinoma cohort * Histologically confirmed diagnosis of cervical carcinoma (adenocarcinoma or squamous carcinomas are eligible). * Recurrent or advanced endometrial carcinoma can be included. * Earlier platin (including concomitant with radiotherapy) therapy is allowed. But earlier weekly or dose-dense regimens with paclitaxel and carboplatin are not allowed. Exclusion Criteria: * Other histologies than those mentioned above such as non-epithelial ovarian carcinomas, neuro-endocrine tumors, sarcomas, metastases from other primary tumors, ... * Earlier weekly or dose-dense paclitaxel and carboplatin regimen. * Any unstable or serious condition e.g. uncontrolled infection requiring systemic therapy. * Prior other malignancies treated primarily or for recurrence within 3 years prior to inclusion in this study, except for completely resected non- melanomatous skin carcinoma or successfully treated in situ carcinoma of the skin or cervix of the uterus. * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures * Metastatic disease to the brain or leptomeninges. * Treatment with any of the following anti-cancer therapies: * radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of study chemotherapy. * chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs similar or related to Paclitaxel, Carboplatin or G-CSF.